Our top pick for
Building a portfolio
AngioDynamics, Inc is a medical instruments & supplies business based in the US. AngioDynamics shares (ANGO) are listed on the NASDAQ and all prices are listed in US Dollars. AngioDynamics employs 800 staff and has a trailing 12-month revenue of around USD$272.5 million.
|52-week range||USD$8.05 - USD$24.5|
|50-day moving average||USD$22.1749|
|200-day moving average||USD$16.7458|
|Wall St. target price||USD$25.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.291|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing AngioDynamics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AngioDynamics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AngioDynamics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, AngioDynamics shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
AngioDynamics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.87. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AngioDynamics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AngioDynamics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$4.7 million.
The EBITDA is a measure of a AngioDynamics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$272.5 million|
|Gross profit TTM||USD$150.3 million|
|Return on assets TTM||-2%|
|Return on equity TTM||-31.75%|
|Market capitalisation||USD$920.3 million|
TTM: trailing 12 months
There are currently 815,034 AngioDynamics shares held short by investors – that's known as AngioDynamics's "short interest". This figure is 27.6% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting AngioDynamics shares can be evaluated.
AngioDynamics's "short interest ratio" (SIR) is the quantity of AngioDynamics shares currently shorted divided by the average quantity of AngioDynamics shares traded daily (recently around 342451.2605042). AngioDynamics's SIR currently stands at 2.38. In other words for every 100,000 AngioDynamics shares traded daily on the market, roughly 2380 shares are currently held short.
However AngioDynamics's short interest can also be evaluated against the total number of AngioDynamics shares, or, against the total number of tradable AngioDynamics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AngioDynamics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 AngioDynamics shares in existence, roughly 20 shares are currently held short) or 0.0306% of the tradable shares (for every 100,000 tradable AngioDynamics shares, roughly 31 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AngioDynamics.
Find out more about how you can short AngioDynamics stock.
We're not expecting AngioDynamics to pay a dividend over the next 12 months.
Over the last 12 months, AngioDynamics's shares have ranged in value from as little as $8.05 up to $24.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AngioDynamics's is 0.818. This would suggest that AngioDynamics's shares are less volatile than average (for this exchange).
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.